Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 10c, Raises FY EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Jazz Pharmaceuticals (JAZZ) Price Target Raised to $190 at UBS
November 5, 2014 9:11 AM ESTUBS maintained a Buy rating on Jazz Pharmaceuticals (NASDAQ: JAZZ) and raised its price target to $190.00 (from $180.00). The change follows Q3 results.
Analyst Marc Goodman said, "It was another solid quarter, and Jazz has clearly demonstrated that 1Q was an anomaly. Xyrem... More
